Advertisement

Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry

      Highlights

      • Patients with ACS and anemia are commonly treated with clopidogrel in routine clinical practice.
      • A not negligible proportion of patients with ACS treated with ticagrelor or prasugrel form this series met criteria of anemia (9.2%).
      • Anemia was an independent predictor of mortality.
      • Despite their higher bleeding risk profile, patients with anemia had an acceptable rate of bleeding at one year (5.4%).

      Abstract

      Introduction

      Ticagrelor and prasugrel are recommended as first line therapy in patients with acute coronary syndromes (ACS). However, patients with anemia are commonly treated with clopidogrel in routine clinical practice. The RENAMI registry (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction) included ACS patients treated with prasugrel or ticagrelor at hospital discharge. The aim of this study was to analyze the prevalence of anemia and characteristics and outcomes of these patients according to anemia status.

      Methods

      Consecutive patients with ACS from 11 centers were included. All patients underwent percutaneous coronary intervention (PCI). Anemia was defined as hemoglobin <130 g/L in men and <120 g/L in women. The incidence of ischemic and bleeding events and all-cause mortality were assessed at one year.

      Results

      From 4424 patients included, 405 (9.2%) fulfilled criteria of anemia. Patients with anemia were significantly older, had a higher prevalence of peripheral artery disease, previous bleeding and renal disfunction and higher bleeding risk (PRECISE-DAPT score ≥ 25: 37.3% vs 18.8%, p < 0.001) The incidence of BARC 3/5 bleeding was moderately higher in patients with anemia (5.4% vs 1.5%, p = 0.001). The incidence of stent thrombosis or reinfarction was not significantly different according to anemia status. Anemia was independently associated with mortality (HR 1.73; 95% CI 1.03-2.91, p = 0.022).

      Conclusions

      A not negligible proportion of patients treated with ticagrelor or prasugrel met criteria for anemia. Anemia was an independent predictor of mortality. Despite their higher bleeding risk profile, patients with anemia had an acceptable rate of bleeding.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bagai A.
        • Bhatt D.L.
        • Eikelboom J.W.
        • et al.
        Individualizing duration of dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention.
        Circulation. 2016; 133: 2094-2098
        • Valgimigli M.
        • Bueno H.
        • Byrne R.
        • et al.
        ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2017; 2017: 1-48
        • Bavishi C.
        • Panwar S.
        • Messerli F.H.
        • et al.
        Meta-analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-elevation acute coronary syndrome.
        Am. J. Cardiol. 2015; 116: 809-817
        • Willis P.
        • Voeltz M.D.
        Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction.
        Am. J. Cardiol. 2009; 104 (34C-8C)
        • Lawler P.R.
        • Filion K.B.
        • Dourian T.
        • et al.
        Anemia and mortality in acute coronary syndromes: a systematic review and meta-analysis.
        Am. Heart J. 2013; 165 (e5): 143-153
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • TRITON-TIMI 38 Investigators
        • et al.
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N. Engl. J. Med. 2007; 357: 2001-2015
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • et al.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N. Engl. J. Med. 2009; 361: 1045-1057
        • Zakai N.A.
        • Katz R.
        • Hirsch C.
        • et al.
        A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study.
        Arch. Intern. Med. 2005; 165: 2214-2220
        • Mehran R.
        • Rao S.V.
        • Bhatt D.L.
        • et al.
        Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
        Circulation. 2011; 123: 2736-2747
        • Kalbfleish J.D.
        • Prentice R.L.
        The Statistical Analysis of Failure Time Data.
        John Wiley & Sons, Nueva York1980: 87-89
      1. Rothman K.J. Greenland S. Modern Epidemiology. Lippincott Raven, Filadelfia1998: 123-125
        • Brener S.J.
        • Mehran R.
        • Dangas G.D.
        • et al.
        Relation of baseline hemoglobin levels and adverse events in patients with acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction Trials).
        Am. J. Cardiol. 2017; 119: 1710-1716
        • Ohana-Sarna-Cahan L.
        • Atar S.
        Clinical outcomes of patients with acute coronary syndrome and moderate or severe chronic anaemia undergoing coronary angiography or intervention.
        Eur. Heart J. Acute Cardiovasc. Care. 2017 May 1; (2048872617707959) (Ahead of print)
        • Montalescot G.
        • Brieger D.
        • Dalby A.J.
        • et al.
        Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence.
        J. Am. Coll. Cardiol. 2015; 66: 832-847
        • Giustino G.
        • Baber U.
        • Sartori S.
        • et al.
        Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.
        J. Am. Coll. Cardiol. 2015; 65: 1298-1310
        • Ennezat P.V.
        • Marechaux S.
        • Pinçon C.
        • et al.
        Anaemia to predict outcome in patients with acute coronary syndromes.
        Arch. Cardiovasc. Dis. 2013; 106 (396): 357-365
        • Liu Y.
        • Yang Y.M.
        • Zhu J.
        • et al.
        Anaemia and prognosis in acute coronary syndromes: a systematic review and meta-analysis.
        J. Int. Med. Res. 2012; 40: 43-55
        • Younge J.O.
        • Nauta S.T.
        • Akkerhuis K.M.
        • et al.
        Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syndromes.
        Am. J. Cardiol. 2012; 109: 506-510
        • Mamas M.A.
        • Kwok C.S.
        • Kontopantelis E.
        • et al.
        Relationship between anemia and mortality outcomes in a national acute coronary syndrome cohort: insights from the UK Myocardial Ischemia National Audit Project Registry.
        J. Am. Heart Assoc. 2016 Nov 19; 5 (pii: e003348)
        • Shiraishi J.
        • Kohno Y.
        • Nakamura T.
        • AMI-Kyoto Multi-Center Risk Study Group
        • et al.
        Prognostic impact of chronic kidney disease and anemia at admission on in-hospital outcomes after primary percutaneous coronary intervention for acute myocardial infarction.
        Int. Heart J. 2014; 55: 301-306
        • Groenveld H.F.
        • Januzzi J.L.
        • Damman K.
        • et al.
        Anemia and mortality in heart failure patients a systematic review and meta-analysis.
        J. Am. Coll. Cardiol. 2008; 52: 818-827
        • Joss N.
        • Patel R.
        • Paterson K.
        • et al.
        Anaemia is common and predicts mortality in diabetic nephropathy.
        QJM. 2007; 100: 641-647
        • Ariza-Solé A.
        • Formiga F.
        • Salazar-Mendiguchía J.
        • et al.
        Impact of anaemia on mortality and its causes in elderly patients with acute coronary syndromes.
        Heart Lung Circ. 2015; 24: 557-565
        • Castini D.
        • Persampieri S.
        • Cazzaniga S.
        • et al.
        Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
        Ther. Adv. Cardiovasc. Dis. 2017; 11: 323-331
        • Schiele F.
        • Puymirat E.
        • Bonello L.
        • et al.
        Switching between thienopyridines in patients with acute myocardial infarction and quality of care.
        Open Heart. 2016; 3e000384https://doi.org/10.1136/openhrt-2015-000384
        • Nordstrom B.L.
        • Simeone J.C.
        • Zhao Z.
        • et al.
        Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention.
        Am. J. Cardiovasc. Drugs. 2013; 13: 263-271
        • Patti G.
        • Cavallari I.
        • Antonucci E.
        • et al.
        Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome.
        PLoS One. 2017 Oct 23; 12e0186961https://doi.org/10.1371/journal.pone.0186961
        • Almendro-Delia M.
        • García-Alcántara A.
        • De la Torre-Prados M.V.
        • et al.
        Safety and efficacy of prasugrel and ticagrelor in acute coronary syndrome. Results of a “Real World” multicenter registry.
        Rev. Esp. Cardiol. 2017; 70: 952-959
        • Bertrand OF
        • Larose E.
        • Rodés-Cabau J.
        • et al.
        Incidence, range, and clinical effect of hemoglobin changes within 24 hours after transradial coronary stenting.
        Am. J. Cardiol. 2010; 106: 155-161
        • Ang D.S.
        • Kao M.P.
        • Noman A.
        • et al.
        The prognostic significance of early and late anaemia in acute coronary syndrome.
        QJM. 2012; 105: 445-454
        • Rousseau M.
        • Yan R.T.
        • Tan M.
        • Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators
        • et al.
        Relation between hemoglobin level and recurrent myocardial ischemia in acute coronary syndromes detected by continuous electrocardiographic monitoring.
        Am. J. Cardiol. 2010; 106: 1417-1422
        • Dan K.
        Thrombocytosis in iron deficiency anemia.
        Intern. Med. 2005; 44: 1025-1026
        • Wadowski P.P.
        • Kopp C.W.
        • Koppensteiner R.
        • et al.
        Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
        Eur. J. Clin. Investig. 2018 Jan; 48https://doi.org/10.1111/eci.12861
        • Zafar M.U.
        • Santos-Gallego C.
        • Vorchheimer D.A.
        • et al.
        Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation.
        J. Thromb. Haemost. 2013; 11: 100-106
        • Costa F.
        • van Klaveren D.
        • James S.
        • PRECISE-DAPT Study Investigators
        • et al.
        Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
        Lancet. 2017 Mar 11; 389: 1025-1034